The company said its direct, wholly owned subsidiary Vectura Fertin Pharma Inc. agreed to sell Vectura Group Ltd. to Molex Asia Holdings Ltd. under a definitive agreement announced on September 17, 2024. Upfront cash consideration is GBP 150 million (approximately $198 million), subject to customary purchase price adjustments.

8-KOther EventsFiled Sep 17, 2024Period of report Sep 17, 2024Summary published (UTC) Oct 25, 2026

Key points

AI summary

The company said its direct, wholly owned subsidiary Vectura Fertin Pharma Inc. agreed to sell Vectura Group Ltd. to Molex Asia Holdings Ltd. under a definitive agreement announced on September 17, 2024. Upfront cash consideration is GBP 150 million (approximately $198 million), subject to customary purchase price adjustments.
Philip Morris International said up to GBP 148 million (approximately $195 million) in deferred payments are contingent on achievement of certain milestones over periods up to and through 2039. It said the transaction is expected to close by the end of 2024, subject to regulatory approval and other customary closing conditions.
The company said it expects to record an estimated loss of approximately $220 million associated with the sale in Q3 2024, following the Board of Directors' approval of the sale on September 12, 2024. It said the amount is subject to working capital and other adjustments.
The company said that, alongside the Vectura sale, master service agreements will be established to develop Vectura Fertin Pharma's proprietary pipeline of inhaled therapeutics. It said the remaining units of Vectura Fertin Pharma will be given a new corporate identity and will continue to operate as a separate company under PMI's ownership.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Vectura Group Sale Agreement and Upfront Cash Consideration

The company said its direct, wholly owned subsidiary Vectura Fertin Pharma Inc. agreed to sell Vectura Group Ltd. to Molex Asia Holdings Ltd. under a definitive agreement announced on September 17, 2024. Upfront cash consideration is GBP 150 million (approximately $198 million), subject to customary purchase price adjustments.

Source · Based on the filing body and exhibits

Milestone-Based Deferred Payments and Closing Timeline

Philip Morris International said up to GBP 148 million (approximately $195 million) in deferred payments are contingent on achievement of certain milestones over periods up to and through 2039. It said the transaction is expected to close by the end of 2024, subject to regulatory approval and other customary closing conditions.

Source · Based on the filing body and exhibits

Estimated Loss of Approximately $220 million Expected in Q3 2024

The company said it expects to record an estimated loss of approximately $220 million associated with the sale in Q3 2024, following the Board of Directors' approval of the sale on September 12, 2024. It said the amount is subject to working capital and other adjustments.

Source · Based on the filing body and exhibits

Vectura Fertin Pharma Remaining Business and Service Agreements

The company said that, alongside the Vectura sale, master service agreements will be established to develop Vectura Fertin Pharma's proprietary pipeline of inhaled therapeutics. It said the remaining units of Vectura Fertin Pharma will be given a new corporate identity and will continue to operate as a separate company under PMI's ownership.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.